this study aimed to investigate the efficacy and safety of drug-eluting beads (deb) transarterial chemoembolization (tace) treatment in chinese intrahepatic cholangiocarcinoma (icc) patients.
37 icc patients underwent deb-tace treatment in ctilc study (registered on clinicaltrials.gov with registry no. nct03317483)
were included in this present study. treatment response was assessed according to modified response evaluation criteria in solid tumors (mrecist). overall survival (os) was calculated from the time of deb-tace operation until the date of death from any causes. liver function change and adverse events (aes) were recorded during and after deb-tace operation.
3 (8.1%) patients achieved complete response (cr) and 22 (59.5%) patients achieved partial response (pr), with objective response rate (orr) of 67.6%. after deb-tace treatment, mean os was 376 days (95%ci: 341–412 days). multivariate logistic regression analysis revealed that bilobar disease (p=.040, or: 0.105, 95% ci: 0.012–0.898) and portal vein invasion (p=.038, or: 0.104, 95% ci: 0.012–0.881) could independently predict less possibility of orr. patients with alb abnormal, tp abnormal, alt abnormal and ast abnormal were increased at 1-week post deb-tace treatment (p=.034, p=.001, p<.001, p=.006, respectively), while returned to the levels at baseline after 1 to 3 months (all p>.050). besides, most of the aes were mild including pain, fever, vomiting, and nausea in this study.
有3例（8.1％）患者获得完全缓解（cr），22例（59.5％）患者获得部分缓解（pr），客观反应率（orr）为67.6％。经过deb-tace治疗后，平均os为376天（95％ci：341–412天）。多元逻辑回归分析显示，病变累及双叶（p=0.040，or：0.105，95％ci：0.012-0.898）和门静脉侵犯（p = .038，or：0.104，95％ci：0.012-0.881）可以独立预测较低的orr。alb，tp，alt异常的患者deb-tace治疗后1周，这些值异常增加（p =0.034，p=.001，p<0.001，p=0.006，而在术后1到3个月可恢复到基线水平（所有p> 0.050）。此外，大多数不良反应（aes）轻微，包括疼痛、发烧、呕吐和恶心。
deb-tace was effective and well tolerated in treating icc patients, and bilobar disease as well as portal vein invasion were independently correlated with less probability of orr achievement.